TRUSCREEN’S NEW PRODUCTION FACILITY FULLY OPERATIONAL & DEL

16 July 2018
NZX Announcement

TRUSCREEN’S NEW PRODUCTION FACILITY FULLY OPERATIONAL & DELIVERS
SIGNIFICANT IMPROVEMENT IN DEVICE PROFITABILITY

Cervical cancer technology company, TruScreen Limited (NZAX:TRU), announces that its newly
commissioned facility to manufacture the diagnostic Opto-electric front end component of its device
in Australia, is now fully operational.
The facility, located in the Industry Collaboration Hub at the Commonwealth Scientific and Industrial
Research Organisation (CSIRO) site in Lindfield Sydney, benefits from knowledge sharing with both
the CSIRO and other high technology organisations co-located at the site.
Commissioned in June 2018 the facility produces the key technical diagnostic (front end) component
of the Truscreen2 device and involves unique and sophisticated opto-electric and biomedical
engineering skills and techniques. The facility is accredited under TruScreen’s internationally
recognized ISO:13485 Quality Certification and includes a skilled team recruited for their specific
expertise in optical and biomedical engineering. Many of the processes involved are unique to
TruScreen, and utilise componentry specifically designed by TruScreen for its unique manufacturing
needs.
Output of the new facility is currently 100 front ends per month which is approximately double the
output under the previous outsourced supply model. As demand for TruScreen increases, this
manufacturing capacity can again be doubled up to 200 units per month. For every 100 devices fully
deployed in a hospital environment in China, a sustainable annuity income stream of approximately
$1.4 million will be generated every year. The majority of this increased production capacity is
required to meet future demand expectations from the Chinese market.
Chairman Mr Robert Hunter stated “the Opto-electric diagnostic (front end) component is a key
element of the TruScreen device and the company’s intellectual property. The establishment of the
company’s own accredited manufacturing facility is a major achievement which will result in an
approximate 50% improvement in gross profit per device. Further cost savings are planned as the
company brings additional manufacturing, assembly, calibration and testing processes inhouse.”
ENDS
For more information visit www.truscreen.com or contact:

Martin Dillon
TruScreen Chief
Executive Officer
Email:
martindillon@truscre
en.com
Media Liaison
Jackie Ellis
Email:
jackie@ellisandco
.co.nz
Phone: +64 27
246 2505

About TruScreen:

TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the
cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to
identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.